Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

  • You can purchase this item in Pay Per ViewPay per View - FAQ : 30,00 € Taxes included to order
    Pages Iconography Videos Other
    8 0 0 0


Archives de pédiatrie
Volume 14, n° S3
pages 186-193 (octobre 2007)
Doi : S0929-693X(07)80026-1
Des caractéristiques structurales et antigéniques des rotavirus au développement des vaccins
From structural and antigenic features of the rotavirus to the development of the vaccines
 

N. Parez 1, , A. Garbarg-Chenon 2
1 Service des urgences pédiatriques, Hôpital d'enfants A.-Trousseau, APHP, 26 rue du Dr Netter, 75571 Paris cedex 12, France. 
2 Laboratoire de virologie (EA 3500, Universitè Pierre-et-Marie-Curie, Paris 6), Hôpital d'enfants A.-Trousseau, APHP, 26 rue du Dr Netter, 75571 Paris cedex 12, France. 

*Correspondance
Résumé

Les rotavirus sont les premiers agents étiologiques responsables des diarrhées sévères dans le monde. La lourde mortalité et l'importante morbidité que l'infection entraîne chaque année à travers le monde en font un véritable enjeu de santé publique. La vaccination semble représenter le seul moyen de prévention efficace contre les gastro-entérites à rotavirus. Deux vaccins vivants atténués (RotaTeq® and Rotarix®) ont récemment requ une autorisation européenne de mise sur le marché. Ils ont été développés selon des stratégies qui utilisent des propriétés différentes du rotavirus et ils font tousles deux preuve d'une bonne tolérance et d'une efficacité satisfaisante pour la prévention des gastro-entérites aiguës sévères à rotavirus.

The full text of this article is available in PDF format.
Abstract

Rotaviruses are the main etiologic agent of severe acute diarrhoea in children under the age of 5, world-wide. Given that the currently available preventive measures to fight against the transmission of RV disease are not sufficiently effective, vaccination likely represents the only efficacious adapted response to the massive impact of this infection. Two RV vaccines (RotaTeq® and Rotarix®) have recently been developed and licensed in the United States and in Europe. The development of these two vaccines has followed two different strategies. Despite their differences, these vaccines are both safe and efficient in protecting young infants against severe rotavirus acute gastroenteritis.

The full text of this article is available in PDF format.

Mots Clés: : Gastro-entérite aiguë, Rotavirus, Vaccination




© 2007  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@